MYO16-AS2

Across TCGA pan-cancer cohorts, MYO16-AS2 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated MYO16-AS2 data layer.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher MYO16-AS2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO16-AS2 expression acts as an unfavorable survival marker, although some lineages such as ESCA and LIHC show a favorable association.

UCS, HNSC, and ACC are the cancer types where MYO16-AS2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Tertile	All	0.068	0.524	<.001	144	view →
HNSC	OS	Tertile	III,IV	0.383	0.644	<.001	141	view →
ACC	DFS	Tertile	All	0.154	0.701	<.001	129	view →
COAD	OS	Tertile	All	0.163	0.870	<.001	81	view →
BLCA	DFS	Tertile	All	0.102	0.599	<.001	69	view →
STAD	OS	Tertile	All	0.515	0.685	.017	21	view →
ESCA	OS	Tertile	III,IV	0.703	0.344	.025	18	view →
KIRP	OS	Tertile	All	0.794	0.950	.030	15	view →
LUSC	OS	Tertile	II,III,IV	0.206	0.414	.037	6	view →
LUAD	OS	Tertile	All	0.115	0.361	.042	6	view →
LIHC	DFS	Tertile	All	0.614	0.420	.042	3	view →
LGG	OS	Tertile	All	0.946	0.865	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

MYO16-AS2–UCS (DFS)

Open the UCS breakdown →